RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced that Dr. Byron Brehm-Stecher presented data yesterday at the “American Society of Microbiology 6th Annual Biodefense and Emerging Diseases Research Meeting” in Baltimore relating to PolyMedix’s proprietary antimicrobial compounds.
